Maqin cough syrup enters Chongqing Medical Insurance Drug List
Chongqing Huafang Wulingshan Pharmaceutical Co., Ltd. has made another breakthrough in the sales of Maqin cough syrup. Maqin cough syrup belongs to the three new national drugs. After reviewing and issuing by experts from Chongqing Municipal Human Resources and Social Security Bureau ("Notice on adding 7 new varieties of Chinese patent medicines to our city's medical insurance drug list"), our county's new drug Maqin cough syrup entered the city as the first of 7 varieties The new version of the medical insurance, work-related injury insurance and maternity insurance drug catalogs will be officially implemented from May 13th.
officially announced its entry into the Chongqing medical insurance catalogue (medical insurance number: 1098), (medical insurance serial number: 222447) on July 23. This means that in a certain period of time in the future, in the use of cough medicines in hospitals above the second level in Chongqing, Maqin cough syrup will become one of its main varieties. After several years of promotion and application in the market, this product is well received by patients.
(Huawu Pharmaceutical): Wang Hui
Announcement of the full text of the environmental impact report of the renovation and expansion project
According to the relevant provisions of the "Environmental Impact Assessment Law" and the "Interim Measures for Public Participation in Environmental Impact Assessment".
The second public announcement of the environmental impact assessment of the reconstruction and expansion project of Kunyao Group Chongqing Wulingshan Pharmaceutical Co., Ltd.
According to the relevant provisions of the "Interim Measures for Public Participation in Environmental Impact Assessment", the relevant information on the environmental impact assessment of the "Reconstruction and Expansion Project of Kunyao Group Chongqing Wulingshan Pharmaceutical Co., Ltd." is now announced.
Kunyao Group Chongqing Wulingshan Pharmaceutical Co., Ltd. Reconstruction and Expansion Project Environmental Impact Assessment Public Participation First Public Announcement
According to the relevant provisions of the "Interim Measures for Public Participation in Environmental Impact Assessment," combined with the characteristics of the construction project
From September 29th to 30th, 2015, the company took pictures after training all employees on safety, GMP, ICQ7, TPM and corporate culture.
Chongqing Huafang Wulingshan Pharmaceutical Co., Ltd. is recognized as a municipal enterprise technology center
Artemisinin, artemether, dihydroartemisinin, artesunate